Help Everyone Live a Healthy Life.


Founded in 2001, Walvax Biotechnology Co., Ltd. (Walvax) is a leading vaccine producer, engaged in research and development, manufacturing and distribution of safe, efficacious and quality vaccines.


Headquartered in China’s southwestern city Kunming in Yunnan Province, Walvax went public via IPO in 2010 (300142.SZ) and started business expansion from traditional vaccines to innovative vaccines.


With the vision of dedicating to be the pride domestically and the pioneer globally in the vaccine industry, producing efficacious, quality, innovative and affordable products to protect people from the world’s deadliest diseases, Walvax’s purpose is to help everyone live a healthy life. 

Walvax has assembled a seasoned core management team consisting of entrepreneurial teams from Chinese Institutes of Biological Products and senior vaccine experts from multinational corporations, as well as 10 senior overseas returnee scientists and over 100 doctor's or master's degree personnel.


In the research and development area, Walvax has two independent subsidiaries: one is Shanghai Zerun Biotechnology Co., Ltd. (Zerun) in Shanghai’s Medicine Valley Zhangjiang, Pudong; the other is Walvax Technical Center in Kunming’s Hi-Tech District. Led by west-trained scientists and vaccine experts, Zerun is working on recombinant virus-based vaccines, with its bi-valent human papillomavirus vaccine (HPV-2) which has filed BLA application and nona-valent HPV vaccine (HPV-9) which has already completed Phase I trial. On the other hand, Walvax Technical Center, dedicated to developing bacterial vaccines, has successfully developed 7 licensed vaccines (10 presentations), including recently approved 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13-TT).

Till date, Walvax has three manufacturing facilities in Yuxi City, Yunnan, Daxing District, Beijing and Taizhou City, Jiangsu, respectively. Located in Yuxi City which is about 40 miles (70 km) south of Kunming, Walvax's commercial manufacturing facility of 130,000 m² floor space is currently manufacturing all licensed and to be licensed vaccines, including HPV-2. The annual capacity for a variety of vaccines at Yuxi facility is about 190 million doses.


Walvax covers markets in 2400 counties (2,846 in total) among 31 provinces (31 in total) in China. As of today, Walvax manufactures and distributes PCV13, Haemophilus influenza type b conjugate vaccine, Group A and C meningococcal polysaccharide vaccine (MPV AC), Group A and group C meningococcal conjugate vaccine (MCV AC), Group ACYW135 meningococcal polysaccharide vaccine (MPV ACYW135), 23-valent pneumococcal polysaccharide (PPSV23) and Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine (DTaP) in China. Beyond China, Walvax has worked closely with business partners to reach overseas markets on the Belt and Road, and has been exporting vaccines to 16 countries, including the United States, Egypt, Indonesia, the Philippines, Bangladesh, Guinea, Nigeria, Senegal, Mauritius, Niger, India, Kyrgyzstan, etc.

In the global collaboration area, Walvax and its subsidiaries have been partnering with academic institutions, industry peers and international organizations. Till date, Walvax has received three grants worth US$ 8.5 million in total during the last 6 years from the Bill & Melinda Gates Foundation to support WHO prequalification for the HPV-2 and HPV-9 in order to prepare for UNICEF procurement for Gavi countries, and to expedite pre-clinical research of Recombinant Subunit SARS-CoV-2 Vaccine as well. In addition, MPV ACYW135 and MCV AC are under PQ assessment, and PCV13 is under PQ preparations.

Performance Innovation Marketing


USD459.2 million revenue in 2020


162.1% increase in revenue since 2019


8 new vaccines and 1 siRNA therapeutics under development


65 authorized invention patents at home and abroad


10+ patents application in progress


cities covered in China


Products exported to 15 countries


countries registration in progress


Engaged 40 partners in 5 continents

Our Journey

Over the past two decades, Walvax has achieved many milestones in developing vaccines.

Learn More



The growth of Walvax is strongly supported by the advancement on developing vaccines.

National-recognized Enterprise Technology Center

Issued by National Development and Reform Commission (NDRC), Ministry of Science and Technology (MOST), Ministry of Finance, The General Administration of Customs (GACC), and State Administration of Taxation (SAT)

National High-tech Industrialization Demonstration Project

Issued by National Development and Reform Commission (NDRC)

High and New Technology Enterprise

Issued by Yunnan Provincial Science and Technology Department, Yunnan Provincial Finance Department, Yunnan Provincial State Taxation Bureau, and Yunnan Provincial Local Taxation Bureau

International Science & Technology Cooperation Base

Issued by Department of International Cooperation, Ministry of Science & Technology of China

Find Out More


Learn about our marketed products.


Learn about our industry-leading manufacturing capacity.


Learn about our reliable and effective distribution capacity.